These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18629360)

  • 1. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention.
    Cuspidi C; Negri F; Zanchetti A
    Vasc Health Risk Manag; 2008; 4(1):67-73. PubMed ID: 18629360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy.
    Wachtell K; Devereux RB; Lyle PA; Okin PM; Gerdts E
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):507-13. PubMed ID: 19124445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor blockers in the prevention of atrial fibrillation.
    Barra S; Silvestri N; Vitagliano G; Madrid A; Gaeta G
    Expert Opin Pharmacother; 2009 Jun; 10(9):1395-411. PubMed ID: 19466911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
    Healey JS; Baranchuk A; Crystal E; Morillo CA; Garfinkle M; Yusuf S; Connolly SJ
    J Am Coll Cardiol; 2005 Jun; 45(11):1832-9. PubMed ID: 15936615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
    Okin PM; Wachtell K; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Lindholm LH; Nieminen MS; Edelman JM; Hille DA; Dahlöf B
    JAMA; 2006 Sep; 296(10):1242-8. PubMed ID: 16968848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.
    Aksnes TA; Flaa A; Strand A; Kjeldsen SE
    J Hypertens; 2007 Jan; 25(1):15-23. PubMed ID: 17143167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta blockers & left ventricular hypertrophy regression.
    George T; Ajit MS; Abraham G
    Indian Heart J; 2010; 62(2):139-42. PubMed ID: 21180305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
    Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
    J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-blockers in Hypertensive Left Ventricular Hypertrophy and Atrial Fibrillation Prevention.
    Koraćević G; Mićić S; Stojanović M; Zdravkovic M; Simić D; Kostić T; Atanasković V; Janković-Tomašević R
    Curr Vasc Pharmacol; 2024; 22(1):19-27. PubMed ID: 38031765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy.
    Kjeldsen SE; Strand A; Julius S; Okin PM
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):487-92. PubMed ID: 16849902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension and atrial fibrillation.
    Go O; Rosendorff C
    Curr Cardiol Rep; 2009 Nov; 11(6):430-5. PubMed ID: 19863867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
    Savelieva I; Kakouros N; Kourliouros A; Camm AJ
    Europace; 2011 Mar; 13(3):308-28. PubMed ID: 21345926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
    Bang CN; Okin PM; Køber L; Wachtell K; Gottlieb AB; Devereux RB
    J Hypertens; 2014 Mar; 32(3):667-72. PubMed ID: 24379001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular hypertrophy and angiotensin II receptor blocking agents.
    Yasunari K; Maeda K; Nakamura M; Watanabe T; Yoshikawa J; Hirohashi K
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Jan; 3(1):61-7. PubMed ID: 15638745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart.
    Fazio G; Pizzuto C; Sutera L; Guttilla D; Di Gesaro G; Cascio C; Novo G; Assennato P; Novo S
    Minerva Cardioangiol; 2007 Jun; 55(3):311-5. PubMed ID: 17534249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.